AR117612A1 - Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica - Google Patents
Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoicaInfo
- Publication number
- AR117612A1 AR117612A1 ARP190102031A ARP190102031A AR117612A1 AR 117612 A1 AR117612 A1 AR 117612A1 AR P190102031 A ARP190102031 A AR P190102031A AR P190102031 A ARP190102031 A AR P190102031A AR 117612 A1 AR117612 A1 AR 117612A1
- Authority
- AR
- Argentina
- Prior art keywords
- pharmaceutical composition
- chewable tablet
- diosmine
- flavonoic fraction
- flavonoic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Heart & Thoracic Surgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Vascular Medicine (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Una composición farmacéutica en la forma de un comprimido masticable fuertemente dosificado en diosmina micronizada. Esta composición farmacéutica comprende entre un porcentaje de diosmina micronizada entre el 20% y el 80% de la masa total de la composición farmacéutica. Esta composición farmacéutica se utiliza en el tratamiento de la insuficiencia venosa y de la crisis hemorroidal.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1856769A FR3083980B1 (fr) | 2018-07-20 | 2018-07-20 | Composition pharmaceutique sous la forme d'un comprime a croquer de diosmine ou d'une fraction flavonoique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR117612A1 true AR117612A1 (es) | 2021-08-18 |
Family
ID=65243687
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP190102031A AR117612A1 (es) | 2018-07-20 | 2019-07-19 | Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica |
Country Status (22)
| Country | Link |
|---|---|
| EP (1) | EP3823588A1 (es) |
| KR (1) | KR20210034036A (es) |
| CN (1) | CN112423735A (es) |
| AR (1) | AR117612A1 (es) |
| AU (1) | AU2019306315B2 (es) |
| BR (1) | BR112021000440A2 (es) |
| CA (1) | CA3106495C (es) |
| CL (1) | CL2021000083A1 (es) |
| CO (1) | CO2021000115A2 (es) |
| CR (1) | CR20210023A (es) |
| EA (1) | EA202190269A1 (es) |
| EC (1) | ECSP21001232A (es) |
| FR (1) | FR3083980B1 (es) |
| JO (1) | JOP20210003A1 (es) |
| MA (1) | MA53159A (es) |
| MX (1) | MX2021000763A (es) |
| NI (1) | NI202100002A (es) |
| PE (1) | PE20210929A1 (es) |
| PH (1) | PH12021550037A1 (es) |
| SG (1) | SG11202100181YA (es) |
| TW (1) | TWI831808B (es) |
| WO (1) | WO2020016408A1 (es) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2661610B1 (fr) * | 1990-05-02 | 1994-09-30 | Rhone Poulenc Sante | Nouvelle forme lyophilisee de la diosmine et sa preparation. |
| FR2661830B1 (fr) * | 1990-05-11 | 1992-09-04 | Corbiere Jerome | Nouvelle compositions pharmaceutiques a base de flavonoside. |
| FR2726469B1 (fr) * | 1994-11-08 | 1996-12-13 | Adir | Composition pharmaceutique pour l'administration orale de flavonoides |
| FR2845597B1 (fr) * | 2002-10-11 | 2005-03-11 | Innothera Lab Sa | Formulation orale seche contenant de la diosmine sous forme pharmaceutique de comprime a croquer |
| ITMI20050517A1 (it) | 2005-03-30 | 2006-09-30 | Therapicon Srl | Composizione farmaceutica di una tipica frazione microcristallina di flavonoidi |
| FR2999934B1 (fr) * | 2012-12-21 | 2015-02-20 | Servier Lab | Composition pharmaceutique sous la forme d'une suspension orale comprenant une fraction flavonoique et de la gomme xanthane |
-
2018
- 2018-07-20 FR FR1856769A patent/FR3083980B1/fr active Active
-
2019
- 2019-07-19 KR KR1020217004706A patent/KR20210034036A/ko active Search and Examination
- 2019-07-19 CR CR20210023A patent/CR20210023A/es unknown
- 2019-07-19 CN CN201980047436.7A patent/CN112423735A/zh active Pending
- 2019-07-19 JO JOP/2021/0003A patent/JOP20210003A1/ar unknown
- 2019-07-19 EP EP19742363.5A patent/EP3823588A1/fr active Pending
- 2019-07-19 CA CA3106495A patent/CA3106495C/fr active Active
- 2019-07-19 MA MA053159A patent/MA53159A/fr unknown
- 2019-07-19 PE PE2021000077A patent/PE20210929A1/es unknown
- 2019-07-19 WO PCT/EP2019/069498 patent/WO2020016408A1/fr unknown
- 2019-07-19 AU AU2019306315A patent/AU2019306315B2/en active Active
- 2019-07-19 AR ARP190102031A patent/AR117612A1/es unknown
- 2019-07-19 MX MX2021000763A patent/MX2021000763A/es unknown
- 2019-07-19 TW TW108125532A patent/TWI831808B/zh active
- 2019-07-19 BR BR112021000440-8A patent/BR112021000440A2/pt unknown
- 2019-07-19 EA EA202190269A patent/EA202190269A1/ru unknown
- 2019-07-19 SG SG11202100181YA patent/SG11202100181YA/en unknown
-
2021
- 2021-01-07 PH PH12021550037A patent/PH12021550037A1/en unknown
- 2021-01-08 EC ECSENADI20211232A patent/ECSP21001232A/es unknown
- 2021-01-08 CO CONC2021/0000115A patent/CO2021000115A2/es unknown
- 2021-01-08 NI NI202100002A patent/NI202100002A/es unknown
- 2021-01-12 CL CL2021000083A patent/CL2021000083A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CL2021000083A1 (es) | 2021-07-30 |
| EA202190269A1 (ru) | 2021-06-15 |
| PE20210929A1 (es) | 2021-05-19 |
| MX2021000763A (es) | 2021-03-29 |
| PH12021550037A1 (en) | 2021-09-27 |
| CR20210023A (es) | 2021-02-22 |
| NI202100002A (es) | 2021-06-22 |
| ECSP21001232A (es) | 2021-02-26 |
| FR3083980A1 (fr) | 2020-01-24 |
| AU2019306315B2 (en) | 2023-03-09 |
| AU2019306315A1 (en) | 2021-02-11 |
| WO2020016408A1 (fr) | 2020-01-23 |
| CA3106495C (fr) | 2023-08-08 |
| CO2021000115A2 (es) | 2021-01-29 |
| KR20210034036A (ko) | 2021-03-29 |
| TWI831808B (zh) | 2024-02-11 |
| TW202019439A (zh) | 2020-06-01 |
| CN112423735A (zh) | 2021-02-26 |
| FR3083980B1 (fr) | 2021-04-16 |
| CA3106495A1 (fr) | 2020-01-23 |
| SG11202100181YA (en) | 2021-02-25 |
| JOP20210003A1 (ar) | 2021-01-10 |
| BR112021000440A2 (pt) | 2021-04-06 |
| MA53159A (fr) | 2021-05-26 |
| EP3823588A1 (fr) | 2021-05-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR057181A1 (es) | Nueva forma de dosificacion de combinacion | |
| PE20230735A1 (es) | Metodos de tratamiento de trastornos del desarrollo con gaboxadol | |
| CL2012000446A1 (es) | Uso de una formulación vesicular tópica que comprende uno o más fosfolípidos y uno o más tensoactivos en una razón molar de 1:1 a 25:1 de fosfolípidos a tensoactivos, para el tratamiento de trastornos dermatosos inflamatorios. | |
| CO5640087A2 (es) | Composiciones de farmacos anti-inflamatorios no esteroideos descongestionantes y anti-histaminicos | |
| PE20211069A1 (es) | Composicion que comprende 5'-metilselenoadenosina, selenoadenosil-l-homocisteina y gama glutamil-metilselenocisteina | |
| CL2011003266A1 (es) | Compuestos derivados de imidazolidin-2-ona, con actividad inhibidora de 17alfa-hidroxilasa/liasa-c17,20; composicion farmaceutica que los comprende; y uso en el tratamiento de inflamacion o cancer, entre otras. | |
| CL2015002304A1 (es) | Formas del metil {4,6-diamino-2- [1- (2-fluorobencil)-1h-pirazolo [3,4-b] piridino-3-il] pirimidino-5-il} metil carbamato | |
| CL2019000485A1 (es) | Uso de pridopidina para el tratamiento de la disminución funcional. | |
| CL2018001686A1 (es) | Métodos y composiciones particularmente para el tratamiento del trastorno por déficit de atención (divisional solicitud 201701026) | |
| NO20062198L (no) | Bradykinin B1 reseptorantagonister | |
| UY35293A (es) | Isotiazoles sustituidos con amino | |
| PA8809601A1 (es) | Combinación anti-retroviral | |
| GT200500266A (es) | Nuevos derivados de pirimidina y su uso | |
| AR106505A1 (es) | Tratamiento de la oligo-ovulación relacionada con esteatosis hepática | |
| AR048587A1 (es) | Composiciones quimicamente estables de 4-hidroxitamoxifeno | |
| CO6771406A2 (es) | Una composición combinada | |
| PE20211805A1 (es) | Formulaciones de un inhibidor de axl/mer | |
| ECSP21031200A (es) | Uso de reboxetina para el tratamiento de narcolepsia | |
| CO6280488A2 (es) | Combinacion farmaceutica | |
| NI202100002A (es) | Composición farmacéutica en la forma de un comprimido masticable de diosmina o de una fracción flavonoica | |
| AR085399A1 (es) | Combinacion antitumoral que comprende cabazitaxel y cisplatino | |
| AR115883A1 (es) | Composición farmacéutica para el tratamiento de la adicción a sustancias psicoactivas y/o para la prevención de las recaídas a dicha adicción | |
| MX2020003786A (es) | Composiciones orales para el tratamiento de reflujo gastroesofagico. | |
| ES2680293B1 (es) | Composición farmacéutica que comprende ácido 2,5 - dihidroxibencenosulfónico o una de sus sales farmacéuticamente aceptables en forma de unidades individualizadas de suministro y procedimiento de fabricación correspondiente | |
| BR112016006244A2 (pt) | métodos de utilização da iga secretora |